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In Brief
Wang et al. demonstrate that D-2-HG
produced by mutant IDH inhibits
alkylated DNA repair enzymes, leading to
DNA damage and sensitizing IDH mutant
cells to alkylating agents. These results
suggest that impairment of DNA repair
may contribute to tumorigenesis driven
by IDH mutations and that alkylating
agents should be explored as a
therapeutic option for IDH-mutated
cancer patients.
Cell Reports
ReportOncometabolite D-2-Hydroxyglutarate Inhibits
ALKBH DNA Repair Enzymes and Sensitizes
IDHMutant Cells to Alkylating Agents
Pu Wang,1,2 Jing Wu,2,3 Shenghong Ma,1 Lei Zhang,4 Jun Yao,4 Katherine A. Hoadley,2,5 Matthew D. Wilkerson,2
Charles M. Perou,2,5 Kun-Liang Guan,1,7,* Dan Ye,1,* and Yue Xiong1,2,6
1Molecular and Cell Biology Lab of Key Laboratory of Molecular Medicine of Ministry of Education and Institutes of Biomedical Sciences,
Shanghai Medical College, College of Life Science, Fudan University, Shanghai 200032, China
2Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
3Department of Neurosurgery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
4Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China
5Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
6Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
7Department of Pharmacology and Moores Cancer Center, University of California at San Diego, La Jolla, CA 92093, USA
*Correspondence: kuguan@ucsd.edu (K.-L.G.), yedan@fudan.edu.cn (D.Y.)
http://dx.doi.org/10.1016/j.celrep.2015.11.029
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARY
Chemotherapy of a combination of DNA alkylating
agents, procarbazine and lomustine (CCNU), and a
microtubule poison, vincristine, offers a significant
benefit to a subset of glioma patients. The benefit
of this regimen, known as PCV, was recently linked
to IDH mutation that occurs frequently in glioma
and produces D-2-hydroxyglutarate (D-2-HG), a
competitive inhibitor of a-ketoglutarate (a-KG). We
report here that D-2-HG inhibits the a-KG-dependent
alkB homolog (ALKBH) DNA repair enzymes. Cells
expressing mutant IDH display reduced repair ki-
netics, accumulate more DNA damages, and are
sensitized to alkylating agents. The observed sensiti-
zation to alkylating agents requires the catalytic ac-
tivity of mutant IDH to produce D-2-HG and can be
reversed by the deletion of mutant IDH allele or over-
expression of ALKBH2 or AKLBH3. Our results sug-
gest that impairment of DNA repair may contribute
to tumorigenesis driven by IDHmutations and that al-
kylating agents may merit exploration for treating
IDH-mutated cancer patients.
INTRODUCTION
Genes encoding for isocitrate dehydrogenases 1 and 2, IDH1
and IDH2, are frequently mutated in grade II and grade III
anaplastic oligodendrogliomas (AO), mixed oligoastrocytomas
and astrocytomas, and WHO grade IV secondary glioblastomas
(GBMs) (>75%) (Parsons et al., 2008) as well as several other
types of human cancer, including acute myeloid leukemia
(AML, 20%), cartilaginous tumors (75%), intrahepatic cholan-
giocarcinomas (10%–23%), angioimmunoblastic T cell lym-
phoma (AITLs, 20%), and melanoma (5%) (reviewed byCell RepCairns and Mak, 2013; Yang et al., 2012). Tumor-derived IDH1
and IDH2 mutations simultaneously cause loss of its normal ac-
tivity, the production of a-ketoglutarate (a-KG, also known as
2-oxoglutarate), and gain of a neomorphic activity, the reduction
of a-KG to D-2-hydroxyglutarate (D-2-HG) (Dang et al., 2009;
Yan et al., 2009; Zhao et al., 2009) . D-2-HG is structurally similar
to a-KG and acts as an antagonist of a-KG to competitively
inhibit multiple a-KG-dependent dioxygenases, including the
JmjC domain-containing histone demethylases (KDMs) and the
TET (ten-eleven translocation) family of DNA hydroxylases
(Chowdhury et al., 2011; Xu et al., 2011). Altered epigenetic regu-
lation is currently considered to be a major mechanism whereby
IDH mutation and D-2-HG exert their oncogenic effects.
The unique property of mutant IDH1/2 in producing an onco-
metabolite that has no known physiological function makes
mutant IDH enzymes as obvious potential therapeutic targets
for the treatment of IDH-mutated tumors (Rohle et al., 2013;
Wang et al., 2013). Clinical studies have also suggested the
presence of a sequela target(s) for treating IDH-mutated gli-
omas. Following an early study showing successful chemo-
therapy for recurrent malignant oligodendroglioma (Cairncross
and Macdonald, 1988), randomized controlled trials were car-
ried out in both the North America (RTOG 9402) and Europe
(EORTC 26951). These studies have shown clear benefits for
both anaplastic oligodendroglioma (AO) and oligoastrocytoma
(AOA) patients who in addition to radiation therapy received
chemotherapy of procarbazine, CCNU/lomustine, and vincris-
tine (PCV) (Cairncross et al., 2013, 2014; Erdem-Eraslan
et al., 2013; van den Bent et al., 2013). PCV benefit was
recently linked to IDH1 mutations with an overall survival of
9.4 years for IDH-mutated patients versus 5.7 years for patients
with wild-type IDH (Cairncross et al., 2014). Of three agents in
PCV regimen, vincristine inhibits microtubule assembly, and
CCNU and procarbazine are DNA alkylating agents. The mo-
lecular mechanism(s) underlying the therapeutic benefits that
are conferred by PCV is not known and is investigated in this
study.orts 13, 2353–2361, December 22, 2015 ª2015 The Authors 2353
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RESULTS
D-2-HG Inhibits ALKBH Enzymes In Vitro
Endogenous (e.g., S-adenosylmethionine, SAM) and environ-
mental (e.g., nitrosoureas) alkylating agents cause methylated
bases in DNA that can be mutagenic and cytotoxic if not re-
paired. The major enzymes repairing the methylated lesions
such as 1-methyladenine (1meA) and 3-methylcytosine (3meC)
are the AlkB proteins. Like the JmjC KDMs and TET proteins,
AlkB belongs to the Fe(II)- and a-KG-dependent dioxygenases
(Falnes et al., 2002) and includes nine distinct genes in human
cells (AlkB homolog ALKBH1 to ALKBH8 and FTO) (Sedgwick
et al., 2007). The function in repairing DNA alkylation lesion has
been demonstrated biochemically in vitro and supported by
the genetic analysis of mutant mice for mammalian ALKBH2
and ALKBH3 (Aas et al., 2003; Dango et al., 2011; Duncan
et al., 2002; Lee et al., 2005; Ringvoll et al., 2006). We therefore
examined the effect of D-2-HG on the activity of ALKBH2 and
ALKBH3 using purified recombinant ALKBH2 and ALKBH3 pro-
teins and DNA oligo containing 1-methyldeoxyadenine (1MedA)
(Figure S1A). We found that purified ALKBH2 and ALKBH3
rapidly (within 1 min) demethylated (repaired) methylated
adenine (Figure S1B). Addition of 0.5 mM D-2-HG resulted in
nearly 50% inhibition of ALKBH2 (Figure S1C). This is consistent
with a previous observation, showing that D-2-HG inhibits DNA
repair enzyme ALKBH2 in vitro, with an IC50 value of 0.424 mM
(Chowdhury et al., 2011). Similarly, ALKBH3 rapidly (within
1 min) repaired methyl-adenine, a reaction that was also in-
hibited by D-2-HG (Figure 1A). Although D-2-HG is a relatively
weak inhibitor of ALKBH2 and ALKBH3 and may not have
significant effect on ALKBH-mediated repair under normal phys-
iological conditions, the high levels of D-2-HG that accumulate in
IDH-mutated gliomas (i.e., 5–35 mmol/l in glioma [Dang et al.,
2009]) suggest that it could significantly impair the ALKBH func-
tion in IDH-mutated cells, like other a-KG-dependent dioxyge-
nases reported to be inhibited by 2-HG (Table S1).
2-HG Inhibits Removal of Alkylating Agent Induced DNA
Damages in Glioma Cells
To investigate whether ALKBH2 and ALKBH3 could be inhibited
by 2-HG in cells, we established U87-MG glioma stable cell lines
expressing wild-type or R132H mutant IDH1 at a level similar to
that of endogenous IDH1 (Figure 1B). These stable cells were
treated with 2 mM methyl methanesulfonate (MMS), which gen-
erates 1-methyldeoxyadenosine (1-MedA). Expression of
mutant IDH1 significantly delayed the repair kinetics, resulting
a 7-fold increase in the half-life of 1-MedA in genomic DNAFigure 1. 2-HG Inhibits ALKBH2 and ALKBH3 and Accumulates DNA D
(A) D-2-HG inhibits the activity of ALKBH3 in vitro, with IC50 values being 3.09 m
(B) 2-HG accumulation causes decreased DNA adduct repair after MMS treatmen
MMS for 1 hr. After the treatment, the cells were cultured in fresh medium contain
by enzyme digestion and was then subjected to LC-MS/MS to determine the co
Shown are average values of triplicated results with SD.
(C–E) 2-HG accumulation causes increased double-strand breaks after MMS trea
exposed to increasing concentrations of MMS for 1 hr. After the treatment, the ce
level of phosphorylated histone variant H2A.X (g-H2AX) was determined by wes
g-H2AX foci was counted from 25 randomly selected cells (E). Shown are averag
Cell Repfrom 0.52 hr in cells expressing wild-type IDH1 to 3.67 hr in cells
expressing R132H mutant IDH1. Unrepaired DNA adduct would
cause DNA double-strand breaks (DSBs). Consistently, when
compared with cells expressing wild-type IDH1, both U87-MG
and U373-MG cells expressing R132H mutant IDH1 exhibited
substantially increased DSBs after MMS treatment, as deter-
mined by both western blot and immunofluorescence using an
antibody to phosphorylated histone variant H2A.X (g-H2AX, Fig-
ures 1C–1E and S1D). Moreover, qRT-PCR analysis showed that
multiple genes from different DNA repair pathways were signifi-
cantly (p < 0.05) upregulated in cells expressing mutant IDH1
when compared to control cells expressing wild-type IDH1 (Fig-
ure S1E). The endogenous protein levels of neither ALKBH2 nor
ALKBH3 were affected by the expression of either wild-type or
mutant IDH1 (Figure S1F). Although IDH1 mutant sensitize cells
to alkylating agents, cells expressing wild-type or mutant IDH1
responded to ultraviolet (UV) light and ionizing radiation (IR) simi-
larly (Figure S1G). Together, these results demonstrate that tu-
mor-derivedmutant IDH1 inhibits the activity of ALKBH enzymes
and results in the accumulation of DNA damages in cells expo-
sure to alkylating agents.
Expression of Tumor-Derived IDH1 Mutant Sensitizes
Cells to Alkylating Agents
E. coli alkB mutants are sensitive to killing by alkylating agents
such as MMS, especially during exponentially doubling (Dinglay
et al., 2000; Kataoka et al., 1983). This defect can be rescued by
the expression of human ALKBH2 and ALKBH3 (Dinglay et al.,
2000; Duncan et al., 2002). The finding that D-2-HG inhibits
ALKBH2 and ALKBH3 led us to test whether cultured human
cells expressing mutant IDH are sensitized to alkylating agents.
We exposed both U87-MGandU373-MGglioblastoma cells sta-
bly expressing wild-type or R132H mutant IDH1 to N-methyl-N0-
nitro-N-nitrosoguanidine (MNNG) or MMS. Cell death and
viability were then assessed by flow cytometry analysis (Fig-
ure 2A), MTT (3-(4,5-dimerthylthiazol-2,5- diphenyltetrazolium
bromide) assay (Figure 2B), and trypan blue exclusion (Fig-
ure 2C). Consistently seen in all three assays, either MNNG or
MMS treatment decreased cell viability in a dose-dependent
manner in both cell lines but hadmore significant (p < 0.05) killing
effects in cells expressing mutant IDH1 compared to cells ex-
pressing wild-type IDH1. Fluorescence-activated cell sorting
(FACS) analysis revealed that treatments with 4 and 5 mM
MMS resulted in 36.1% and 61.4% Annexin-PI double-positive
cells, respectively, in cells expressing R132H mutant, signifi-
cantly higher than the cells expressing wild-type IDH1 (20.9%
and 42.3%, respectively, Figure S2). Knockdown ALKBH2 withamages
M. Shown are average values of triplicated results with SD.
t. U87-MG cells stably expressing the indicated proteins was treated with 2mM
ing noMMS for the indicated time. Genomic DNA was hydrolyzed to nucleotide
ncentrations of deoxyadenosine (dA) and 1-methyldeoxyadenosine (1MedA).
tment. U87-MG and U-373 cells stably expressing the indicated proteins were
lls were cultured in fresh medium containing no MMS for another 10 hr, and the
tern blot (C) and immunofluorescence (D). Scale bar, 100 mm. The number of
e values of triplicated results with SEM.
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Figure 2. Expression of Tumor-Derived
Mutant IDH1 Sensitizes Cells to Alkylating
Agents
U87-MG and U373-MG cells stably expressing the
indicated proteins were exposed to increasing
concentrations of MNNG orMMS for 1 hr. The cells
were cultured in fresh medium containing no al-
kylating agents for another 47 hr.
(A–C) After that, cell death was assessed by per-
forming flow cytometry analysis (A), MTT assay (B),
and trypan blue staining for viable cell counting (C).
Shown are average values of triplicated results
with SD. *p < 0.05 for cells expressing mutant IDH1
versus wild-type IDH1; n.s., not significant.
(D) Knockdown ALKBH2 sensitize U87-MG cells
expressing wild-type, but not mutant IDH1 toMMS
treatment. Cell death was assessed by flow cy-
tometry analysis (right panel).two different shRNAs in MMS-treated cells increased the death
of U87-MG (wild-type IDH1) cells (Figure 2D), indicating a role
of ALKBH2 in protecting U87-MG cells from MMS-induced
death. In contrast, depletion of ALKBH2 did not synergistically
increase MMS-induced cell death in U87-MG (IDH1R132H) cells.
This result is consistent with the notion that the activity of
ALKBH2 in protecting MMS-induced cell death requires the2356 Cell Reports 13, 2353–2361, December 22, 2015 ª2015 The Authorsa-KG-dependent catalytic function that
is inhibited by the high level of D-2-HG
accumulated in the U87-MG (IDH1R132H)
cells.
Alkylating Agents Sensitizing Effect
of Mutant IDH1 Is Dependent on
2-HG and Can Be Partially Reduced
by Overexpression of ALKBH2 and
ALKBH3
To determine directly whether the sensiti-
zation to alkylating agents by IDH1 muta-
tion is dependent on 2-HG, we introduced
a second mutation into the D-2-HG-pro-
ducing IDH1R132H mutant to disrupt its
binding to a-KG, which is required for
the production of D-2-HG through the
NADPH-dependent reduction of a-KG
(Dang et al., 2009). Six IDH1 double mu-
tants, R132H/T77A, R132H/S94A,
R132H/N96A, R132H/Y139A, R132H/
K212Q, and R132H/T214Awere identified
whose catalytic activity to produce D-2-
HG was markedly reduced (Figures 3A
and 3B). We then established U87-MG
cells stably expressing IDH1, IDH1R132H,
IDH1R132H/T77A, or IDH1R132H/S94A (Fig-
ure S3A) and exposed these stable cells
to different concentrations of MMS or
MMNG. We observed that the sensitiza-
tion to MMS and MMNG, conferred by
R132H mutant IDH1, was completelyabolished by second mutations that eliminated 2-HG production
(Figure 3C). Supporting this conclusion, disruption of 2HG-pro-
ducing activity also hinders the activation of DNA repair genes
by the mutant IDH1 (Figures S3B and 3D).
HT1080 fibrosarcoma cells carry heterozygous R132C muta-
tion in IDH1 (IDH1+/R132C) (Amary et al., 2011). We deleted the
R132C mutant allele from HT1080 by TALEN technique and
(legend on next page)
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generated the IDH1+/ cell line (Ma et al., 2015). GC-MS analysis
confirmed that 2-HG was produced in the parental IDH1+/R132C
cells but was not detectable in the IDH1+/ cells (Figure 3E).
We found that deletion of the R132C mutant allele reduced the
sensitivity of HT1080 cells to both MMS and MNNG alkylating
agents (Figure 3F). We next stably overexpressed ALKBH2 or
ALKBH3 in IDH1+/R132C and IDH1+/ HT1080 cells by retrovirus
transduction (Figure 3G). We found that overexpression of either
ALKBH partially rescued the sensitivity in parental IDH1+/R132C
cells, but not in the IDH1+/ cells, to MMS treatment (Figure 3H).
Taken together, we conclude that the ability of mutant IDH1 to
sensitize cells to DNA alkylating agents is dependent on its cat-
alytic activity to produce 2-HG.
Mutant IDH1 Sensitizes Cells to Therapeutic Alkylating
Drugs
To explore the potential clinical significance of sensitizing effects
by mutant IDH to alkylating agents, we examined the responses
of cells expressing either wild-type or mutant IDH1 to busulfan,
an alkylator that has commonly been used to treat chronic
myeloid leukemia (CML) before the advent of imatinib. We found
that U87-MG cells expressing R132H mutant IDH1 were signifi-
cantly more sensitive to busulfan than control cells expressing
wild-type IDH1, and that the enhanced sensitivity was
completely abolished by the mutations disrupting D-2-HG pro-
duction (Figure 4A).
Of three agents inPCV regimen, vincristine inhibitsmicrotubule
assembly, and CCNU and procarbazine are DNA alkylating
agents. We found that the expression of R132H mutant IDH1 in
U87-MG cells caused significant sensitivity to CCNU compared
with the expression of wild-type IDH1 (Figure 4B). In contrast,
treatment of cell with vincristine, while effectively reduced cell
viability, exhibited indistinguishable effect toward cells express-
ing either the wild-type or mutant IDH1. Moreover, compared to
cells treated with CCNU alone, combined exposure to CCNU
andprocarbazine orCCNUandvincristine hadnoadditive or syn-
ergistic effect on thekillingof cells expressingmutant orwild-type
IDH1 (Figure 4C). Furthermore, overexpression of either ALKBH2
or ALKBH3 partially reduced the death HT1080 cells exposed to
CCNU (Figure 4D), supporting the notion that IDH1 mutation andFigure 3. Alkylating Agents Sensitizing Effect of Mutant IDH1 Is Depen
(A and B) Characterization of 2-HG producing activity of IDH1 double mutants. The
both the rate of NADPH oxidation (A) andGC-MS analysis (B). Peaks at 19.6min w
bis-TBDMS 2-HG-specific 433-m/z fragment is shown in the insert. Moreover, the
and glutamate (Glu), respectively. **p < 0.01 by Student’s t test between IDH1R1
(C) U87-MG cells stably expressing the indicated proteins were exposed to increa
flow cytometry analysis and trypan blue staining for viable cell counting.
(D) The mRNA expression of selected DNA repair genes was tested in U87-MG
analysis.
(E) HT1080 (IDH1+/) cell line was generated by knocking out the R132C allele in
tracted from HT1080 (IDH1+/) and parental HT1080 (IDH1+/R132C) cells were sub
(IDH1+/) cells.
(F) HT1080 (IDH1+/) and parental HT1080 (IDH1+/R132C) cells were exposed to i
forming flow cytometry analysis and trypan blue staining for viable cell counting.
(IDH1+/) versus parental HT1080 (IDH1+/R132C) cells.
(G and H) Parental HT1080 (IDH1+/R132C) and TALEN-edited HT1080 (IDH1+/) c
retrovirus transduction. Expression of ALKBH was verified by western blot (G). Th
MTT assay (H).
2358 Cell Reports 13, 2353–2361, December 22, 2015 ª2015 The Au2-HG accumulation sensitize HT1080 cells to CCNU by inhibiting
the activity of ALKBH. The rescue by overexpressed ALKBH did
not reach complete, likely due to the high levels of 2-HGaccumu-
lated in the cells. These results provide a plausible molecular
explanation for the link between PCV benefit and IDH mutation
observed theclinical trials. The interpretationof lackof sensitizing
effect by IDH mutation to procarbazine needs to be cautious
as procarbazine becomes active only after it is metabolized by
cytochrome p450 and monoamine oxidase, mainly in the liver
(Weinkam and Shiba, 1978), and works poorly in non-hepatic
cells lacking high oxidase activity (Swaffar et al., 1989).
DISCUSSION
This study provides two insights into the IDHmutation. First, our
results suggest a mechanism by which IDHmutation contributes
to tumorigenesis. There is strong evidence that IDH1/2 muta-
tions alter epigenetic regulation in affected cells (Chowdhury
et al., 2011; Figueroa et al., 2010; Noushmehr et al., 2010; Sasaki
et al., 2012; Xu et al., 2011). We show in this study that in addition
to altering epigenetic control, impairment of DNA repair may also
contribute to tumorigenesis driven by IDHmutation. Second, the
results presented here implicate a targeted therapy for treating
patients with IDH1/2-mutated tumors. As demonstrated in this
study, glioma cells or chondrosarcoma cells with expression of
mutant IDH1 are significantly more sensitive to MNNG, MMS,
busulfan, and CCNU, compared to cells expressing only wild-
type IDH1, suggesting that the classical alkylating agents may
be an appropriate and ‘‘targeted’’ therapy for patients with
IDH1/2-mutated cancers. This hypothesis is supported by the
results of the aforementioned trials showing that four to six cy-
cles of PCV were sufficient with RT to double the survival of pa-
tients with AO and AOA (Cairncross et al., 2013; Erdem-Eraslan
et al., 2013; van den Bent et al., 2013). The PCV benefit was
recently linked to IDH mutation (Cairncross et al., 2014). Our
study provides a molecular basis for the PCV benefit linked to
IDHmutation. Our finding that IDHmutation and 2HG accumula-
tion sensitize cells to CCNU also suggests that whether future in-
hibitor targeting mutant IDH and blocking the D-2HG production
should be used in combination with PCV need to be investigated.dent on 2-HG
activity of various IDH1 double mutants in producing 2-HGwas determined by
ere identified as bis-TBDMSD-derived 2-HG by themass fragment spectra. The
peaks at 18.9 and 20.3 min were identified as the derivatives of aspartate (Asp)
32H and IDH1.
sing concentrations of MNNG or MMS. Cell death was assessed by performing
cells stably expressing the indicated proteins, as determined by qRT-PCR
parental HT1080 (IDH1+/R132C) cells using TALEN technique. Metabolites ex-
jected to GC-MS analysis, showing the loss of 2-HG accumulation in HT1080
ncreased concentrations of MNNG or MMS. Cell death was assessed by per-
Shown are average values of triplicated results with SD. *p < 0.05 for HT1080
ells stably expressing FLAG tagged ALKBH2 or ALKBH3 were established by
e sensitivity of both IDH1+/R132C and IDH1+/ cells to MMS was determined by
thors
(legend on next page)
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In addition to glioma, IDH1 and IDH2 mutations also occur at
high frequency in several other types of human malignancies.
There is no obvious reason that sensitization to DNA alkylating
agents conferred bymutant IDH and D-2-HG is unique to glioma.
We have demonstrated in this study that chondrosarcoma cells
harboring IDH1 mutation are sensitive to alkylating agent in a
manner that is dependent on the mutant IDH1. A number of
FDA-approved DNA alkylating agents, such as CCNU and
busulfan, have long been used in clinical for cancer treatment.
They may merit for further exploration for treatment of other
IDH-mutated tumors.
EXPERIMENTAL PROCEDURES
Please refer to Supplemental Experimental Procedures for more detailed infor-
mation about procedures for protein expression and purification; in vitro
ALKBH2 and ALKBH3 activity assay; cell culture, treatment, transfection,
viability assay; metabolite extraction and LC-MS/MS analysis of nucleosides.
Antibodies, Plasmids, and Chemicals
Antibodies against Flag (ShanghaiGenomics), b-actin (Genescript), H2AX
(Sigma-Aldrich), IDH1, ALKBH2, ALKBH3 (Epitomics), and phosph-g-H2AX
(Santa Cruz Biotechnology) were purchased commercially.
ALKBH2 and ALKBH3 cDNAs were kind gifts from the Han Jiahuai’s Lab,
Xiamen University and subcloned into pSJ3 for the expression and purification
in E. coli. Wild-type and mutant IDH1 was constructed into pcDNA3.1 for tran-
sient expression or pBABE-puro for stable transduction by retrovirus. ALKBH2
and ALKBH3 were constructed into pBABE-hygro for stable transduction.
shRNAs targeting ALKBH2 are cloned into pLKO.1, and the sequence is listed
in Table S2.
MNNG (Tokyo Chemical Industry, TCI), MMS (Sigma-Aldrich), Temozolo-
mide (TCI), busulfan (TCI), procarbazine/CCNU (Selleckchem), and vincristine
(Selleckchem) were purchased commercially.
RNA Isolation and qRT-PCR Analysis
Total RNA was isolated from cultured cells using Trizol reagent (Invitrogen)
following the manufacturer’s instructions. RNA was reversely transcribed
with oligo-dT primers and preceded to qRT-PCR with gene-specific primers
in the presence of SYBR Premix Ex Taq (TaKaRa). b-actin was used as a
housekeeping control. Primer sequences are listed in Table S2.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.11.029.
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